Current treatment options for CHF management: Focus on the renin-angiotensin-aldosterone system

  • Olaf Hedrich
  • Richard D. Patten
  • David De Nofrio
Article

Optional statement

Heart failure (HF) is highly prevalent in our society and its incidence is increasing in concert with the growing aged population. Experimental and clinical studies have consistently shown that HF is ameliorated by inhibition of the reninangiotensin-aldosterone system (RAAS). Acknowledging that heightened activation of the RAAS contributes significantly to HF progression has led to the development of pharmacologic antagonists of RAAS components that have greatly improved both symptoms and prognosis of patients suffering from this syndrome. Angiotensinconverting enzyme (ACE) inhibitors represent the first developed agents that block the production of angiotensin II, and have been shown to be effective across a broad spectrum of patients with HF, including those with asymptomatic left ventricular dysfunction to overt HF. Initiation of ACE inhibitors prior to the onset of symptoms in those with left ventricular systolic dysfunction, and as early as feasible following a myocardial infarction, has been shown to reduce mortality and the development of overt HF in several clinical trials. Clinical data also support the use of angiotensin II receptor antagonists as an alternative to ACE inhibitors in patients who are allergic to, or intolerant of, ACE inhibitors. Agents that antagonize aldosterone via blockade of mineralocorticoid receptors improve clinical outcomes in patients with advanced HF or those with reduced ejection fraction and HF following an acute myocardial infarction. Maximally inhibiting the RAAS, in conjunction with other neurohormonal systems (eg, the sympathetic nervous system by β-adrenergic blockade), leads to improved clinical outcomes in HF, a highly prevalent and costly disease in our society.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2003.Google Scholar
  2. 2.
    Atlas SA, Case DB, Sealey JE, et al.: Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1979, 1:274–280.PubMedGoogle Scholar
  3. 3.
    Goodfriend TL, Elliott ME, Catt KJ: Angiotensin receptors and their antagonists. N Engl J Med 1996, 334:1649–1654.PubMedCrossRefGoogle Scholar
  4. 4.
    Burnier M, Brunner H: Angiotensin II receptor antagonists. Lancet 2000, 355:637–645.PubMedCrossRefGoogle Scholar
  5. 5.
    Balcells E, Meng QC, Johnson WH Jr, et al.: Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997, 273:H1769-H1774.PubMedGoogle Scholar
  6. 6.
    Ihara M, Urata H, Kinoshita A, et al.: Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999, 33:1399–1405.PubMedGoogle Scholar
  7. 7.
    Biollaz J, Brunner HR, Gavras I, et al.: Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982, 4:966–972.PubMedCrossRefGoogle Scholar
  8. 8.
    Sadoshima J, Izumo S: Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res 1993, 73:413–423.PubMedGoogle Scholar
  9. 9.
    Siragy HM, Carey RM: The subtype 2 (AT2) angiotensin receptor mediated renal production of nitric oxide in conscious rats. J Clin Invest 1997, 100:264–269.PubMedGoogle Scholar
  10. 10.
    Siragy HM, Inagami T, Ichiki T, Carey RM: Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci U S A 1999, 96:6506–6510.PubMedCrossRefGoogle Scholar
  11. 11.
    Patten RD, Soman P: Prevention and reversal of LV remodeling with neurohormonal inhibitors. Curr Treat Options Cardiovasc Med 2004, 6:313–325. An excellent review of this topic presented in a managementbased format.PubMedGoogle Scholar
  12. 12.
    Tamura T, Onodera T, Said S, Gerdes AM: Correlation of myocyte lengthening to chamber dilation in the spontaneously hypertensive heart failure (SHHF) rat. J Mol Cell Cardiol 1998, 30:2175–2181.PubMedCrossRefGoogle Scholar
  13. 13.
    Beltrami CA, Finato N, Rocco M, et al.: The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol 1995, 27:291–305.PubMedGoogle Scholar
  14. 14.
    Kawano H, Do YS, Kawano Y, et al.: Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000, 101:1130–1137.PubMedGoogle Scholar
  15. 15.
    Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and the renin-angiotensinaldosterone system. Circulation 1991, 83:1849–1865.PubMedGoogle Scholar
  16. 16.
    Lombes M, Oblin ME, Gasc JM, et al.: Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992, 71:503–510.PubMedGoogle Scholar
  17. 17.
    Mizuno Y, Yoshimura M, Yasue H, et al.: Aldosterone production is activated in failing ventricle in humans. Circulation 2001, 103:72–77.PubMedGoogle Scholar
  18. 18.
    Yamamoto N, Yasue H, Mizuno Y, et al.: Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 2002, 39:958–962.PubMedCrossRefGoogle Scholar
  19. 19.
    Young M, Fullerton M, Dilley R, Funder J: Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994, 93:2578–2583.PubMedGoogle Scholar
  20. 20.
    Diet F, Pratt RE, Berry GJ, et al.: Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996, 94:2756–2767.PubMedGoogle Scholar
  21. 21.
    Weiss D, Kools JJ, Taylor WR: Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001, 3:448–454.Google Scholar
  22. 22.
    Nickenig G, Harrison DG: The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002, 105:530–536.PubMedCrossRefGoogle Scholar
  23. 23.
    Daugherty A, Manning MW, Cassis LA: Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000, 105:1605–1612.PubMedGoogle Scholar
  24. 24.
    Han Y, Runge MS, Brasier AR: Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factorkappa B transcription factors. Circ Res 1999, 84:695–703.PubMedGoogle Scholar
  25. 25.
    Kranzhofer R, Schmidt J, Pfeiffer CAH, et al.: Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000, 19:1623:1629.Google Scholar
  26. 26.
    Tummala PE, Chem XL, Sundell CL, et al.: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature. A potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999, 100:1223–1229.PubMedGoogle Scholar
  27. 27.
    Chen XL, Tummala PE, Olbrych MT, et al.: Angiotensin II induces monocyte chemoattractant protein-1 gene in rat vascular smooth muscle cells. Circ Res 1998, 83:952–959.PubMedGoogle Scholar
  28. 28.
    Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al.: Inflammation and angiotensin II. Int J Biochem Cell Biol 2003, 35:881–900.PubMedCrossRefGoogle Scholar
  29. 29.
    Nakamura S, Nakamura I, Ma L, et al.: Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000, 58:251–259.PubMedCrossRefGoogle Scholar
  30. 30.
    Brown NJ, Vaughan DE: Prothrombotic effects of angiotensin. Adv Intern Med 2000, 45:419–429.PubMedGoogle Scholar
  31. 31.
    Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995, 95:995–1001.PubMedCrossRefGoogle Scholar
  32. 32.
    Pfeffer MA, Greaves SC, Arnold JMO, et al.: Early vs. delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction: the Healing and Early Afterload Reducing Therapy trial. Circulation 1997, 95:2643–2651.PubMedGoogle Scholar
  33. 33.
    Strawn WB, Chappell MC, Dean RH, et al.: Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000, 101:1586–1593.PubMedGoogle Scholar
  34. 34.
    Pitt B: The anti-ischemic potential of angiotensinconverting enzyme inhibition: insights from the heart outcomes prevention evaluation trial. Clin Cardiol 2000, 23:IV9-IV14.PubMedCrossRefGoogle Scholar
  35. 35.
    Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.PubMedCrossRefGoogle Scholar
  36. 36.
    Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group [no authors listed].N Engl J Med 1987, 316:1429–1435.Google Scholar
  37. 37.
    Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators [no authors listed]. N Engl J Med 1991, 325:293–302.Google Scholar
  38. 38.
    Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators [no authors listed]. N Engl J Med 1992, 327:685–691.Google Scholar
  39. 39.
    Packer M, Poole-Wilson PA, Armstrong PW, et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure: ATLAS Study Group. Circulation 1999, 100:2312–2318.PubMedGoogle Scholar
  40. 40.
    Heart Failure Society of America: HFSA Practice Guidelines: Guidelines for Management of Patients With Heart Failure Caused by Left Ventricular Systolic Dysfunction-Pharmacological Approaches. http://www.hfsa.org/pdf/lvsd_heart_failure.pdf.Accessed August 7, 2004.Google Scholar
  41. 41.
    Drug Topics Red Book. Edited by Cohen HE. Montvale, NJ: Thomson PDR; 2003.Google Scholar
  42. 42.
    GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza Nell’infarto Miocardico [no authors listed]. Lancet 1994, 343:1115–1122.Google Scholar
  43. 43.
    ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Fourth International Study of Infarct Survival (ISIS-4) Collaborative Group [no authors listed]. Lancet 1995, 345:669–685.Google Scholar
  44. 44.
    Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992, 327:669–677.PubMedCrossRefGoogle Scholar
  45. 45.
    Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators [no authors listed]. Lancet 1993, 342:821–828.Google Scholar
  46. 46.
    Kober L, Torp-Pedersen C, Carlsen JE, et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995, 333:1670–1676.PubMedCrossRefGoogle Scholar
  47. 47.
    American College of Cardiology Foundation and the American Heart Association, Inc.: ACC/AHA Practice Guidelines-Full Text: ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction. http://www.acc.org/clinical/guidelines/stemi/index.pdf. Accessed August 7, 2004.Google Scholar
  48. 48.
    Massie BM, Teerlink JR: Interaction between aspirin and angiotensin-converting enzyme inhibitors: real or imagined. Am J Med 2000, 109:431–433.PubMedCrossRefGoogle Scholar
  49. 49.
    Al-Khadra AS, Salem DN, Rand WM, et al.: Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial. J Am Coll Cardiol 1998, 1:419–425.CrossRefGoogle Scholar
  50. 50.
    Peterson JG, Topol EJ, Sapp SK, et al.: Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med 2000, 109:371–377. A concise and balanced perspective on this common clinical question.PubMedCrossRefGoogle Scholar
  51. 51.
    Pitt B, Segal R, Martinez FA, et al.: Randomized trial of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study (ELITE II). Lancet 2000, 355:1582–1587.PubMedCrossRefGoogle Scholar
  52. 52.
    Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure (Val-HeFT). N Engl J Med 2001, 345:1667–1675.PubMedCrossRefGoogle Scholar
  53. 53.
    Maggioni AP, Anand I, Gottlieb SO, et al.: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002, 40:1414–1421.PubMedCrossRefGoogle Scholar
  54. 54.
    Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on morbidity and mortality in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759–766.PubMedCrossRefGoogle Scholar
  55. 55.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906.PubMedCrossRefGoogle Scholar
  56. 56.
    Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized aldactone evaluation study investigators. N Engl J Med 1999, 341:709–717.PubMedCrossRefGoogle Scholar
  57. 57.
    Juurlink DN, Mamdani MM, Lee DS, et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543–551.PubMedCrossRefGoogle Scholar
  58. 58.
    Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2005

Authors and Affiliations

  • Olaf Hedrich
  • Richard D. Patten
  • David De Nofrio
    • 1
  1. 1.Department of Medicine, Division of Cardiology, Tufts-New England Medical CenterCardiac Transplantation Program and Cardiomyopathy CenterBostonUSA

Personalised recommendations